Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
OpenAI in talks with Samsung to power AI features, report says
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
S. Korea not to attend Sado mine memorial: foreign ministry
-
8
South Korean military plans to launch new division for future warfare
-
9
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
10
North Korean leader ‘convinced’ dialogue won’t change US hostility
Celltrion's COVID-19 antibody treatment wins emergency approval in Peru
By YonhapPublished : Nov. 22, 2021 - 14:51
South Korean pharmaceutical giant Celltrion Inc. said Monday its COVID-19 antibody treatment has won an emergency approval from Peruvian authorities.
The drug authority in the South American country granted the approval for an emergency application of Rekirona to adult COVID-19 patients.
The approval was based on recent top-line results from a global phase three clinical study of Rekirona, a pivotal part of the study to obtain more comprehensive safety and efficacy results.
Rekirona is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure.
It takes the form of an intravenous injection that is directly injected for 60 minutes.
In February, Rekirona won the South Korean drug safety agency's conditional approval, becoming the first locally made treatment for COVID-19.
The drug further won overseas approval for an emergency application in Indonesia and Brazil.
Celltrion said Rekirona reduces the risk of COVID-19 progressing to severe levels. The company said the antibody treatment also reduced the recovery time. (Yonhap)
The drug authority in the South American country granted the approval for an emergency application of Rekirona to adult COVID-19 patients.
The approval was based on recent top-line results from a global phase three clinical study of Rekirona, a pivotal part of the study to obtain more comprehensive safety and efficacy results.
Rekirona is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure.
It takes the form of an intravenous injection that is directly injected for 60 minutes.
In February, Rekirona won the South Korean drug safety agency's conditional approval, becoming the first locally made treatment for COVID-19.
The drug further won overseas approval for an emergency application in Indonesia and Brazil.
Celltrion said Rekirona reduces the risk of COVID-19 progressing to severe levels. The company said the antibody treatment also reduced the recovery time. (Yonhap)
